Date: 2015-01-12
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Arena Pharmaceuticals (USA - CA)
Product: ralinepag
Action
mechanism: Ralinepag is an orally available agonist of the prostacyclin (IP) receptor. In Phase 1 trials, ralinepag showed an approximate 25-hour half-life, indicating that the compound could be dosed once or twice daily.
Disease: Pulmonary Arterial Hypertension
Therapeutic area: Rare diseases - Cardiovascular diseases - Respiratory diseases
Country:
Trial details:
Latest
news: * On January 12, 2015, Arena Pharmaceuticals announced the initiation of patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). This 22-week, randomized, double-blind and placebo-controlled Phase 2 trial will evaluate the hemodynamic and exercise capacity effects, safety and tolerability of ralinepag in up to 60 patients with PAH. During the first nine weeks of the trial, patients will be titrated to their individual tolerance level, and then sustained at this level for the remainder of the trial.
